REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Results of Operations and Financial ConditionItem 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On August 3, 2017, Revance Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
|
Item 2.02 |
FINANCIAL STATEMENTS AND EXHIBITS. |
(d) Exhibits
|
Number |
Description |
|
99.1 |
Press Release dated August 3, 2017. |
Revance Therapeutics, Inc. ExhibitEX-99.1 2 rvncq2178-kexhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Revance Releases Second Quarter 2017 ResultsNEWARK,…To view the full exhibit click here
About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.
